Oromandibular dystonia questionnaire (OMDQ-25): a valid and reliable instrument for measuring health-related quality of life.
OBJECTIVE
To develop and validate a disease-specific instrument to measure health-related quality of life in patients with oromandibular dystonia.


METHODS
Prospective, cross-sectional observational study.


METHODS
Tertiary referral clinic, North East England, UK.


METHODS
The Oromandibular Dystonia Questionnaire (OMDQ-25) was evaluated in a group of 30 patients for psychometric properties, including its sensitivity to change after Botulinum Toxin A treatment. Comparison to a generic instrument was enabled using the Glasgow Health Scale Inventory and the Glasgow Benefit Inventory (GBI).


RESULTS
Item generation passed tests for scaling assumptions. Reliability was proven (Cronbach's α > 0.78; test-retest > 0.9) and validity supported with both convergent validity and discriminant validity. Sensitivity to change after Botulinum Toxin A treatment was established for all subscales (P ≤ 0.005), and in comparison with the GBI, all subscales showed large effect sizes.


CONCLUSIONS
The Oromandibular Dystonia Questionnaire (OMDQ-25) is the first reliable and valid instrument to measure health-related quality of life in patients with oromandibular dystonia.
ENT Department, James Cook University Hospital, Middlesbrough, UK. merzr@uhbs.ch
R I
RI
Merz
J
J
Deakin
M R
MR
Hawthorne
D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008538:Meige Syndrome / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology*; D008875:Middle Aged; D019370:Observation; D011446:Prospective Studies; D011594:Psychometrics; D011788:Quality of Life; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D011795:Surveys and Questionnaires
D019274:Botulinum Toxins, Type A